Glycine propionyl-L-carnitine produces enhanced anaerobic work capacity with reduced lactate accumulation in resistance trained males

Patrick L Jacobs, Erica R Goldstein, Will Blackburn, Ihsan Orem, John J Hughes, Patrick L Jacobs, Erica R Goldstein, Will Blackburn, Ihsan Orem, John J Hughes

Abstract

Background: Recent research has indicated that short term administration of glycine propionyl-L-carnitine (GPLC) significantly elevates levels of nitric oxide metabolites at rest and in response to reactive hyperaemia. However, no scientific evidence exists that suggests such supplementation enhances exercise performance in healthy, trained individuals. The purpose of this study was to examine the effects of GPLC on the performance of repeated high intensity stationary cycle sprints with limited recovery periods in resistance trained male subjects.

Methods: In a double-blind, placebo-controlled, cross-over design, twenty-four male resistance trained subjects (25.2 +/- 3.6 years) participated in two test sessions separated by one week. Testing was performed 90 minutes following oral ingestion of either 4.5 grams GPLC or 4.5 grams cellulose (PL), in randomized order. The exercise testing protocol consisted of five 10-second Wingate cycle sprints separated by 1-minute active recovery periods. Peak (PP) and mean values (MP) of sprint power output and percent decrement of power (DEC) were determined per bout and standardized relative to body masss. Heart rate (HR) and blood lactate (LAC) were measured prior to, during and following the five sprint bouts.

Results: Significant main effects (p < 0.001) were observed for sprint bout order in values of PP, MP, DEC, and HR. There were significant main effects detected for condition in PP and MP (p < 0.05), with values across the five sprint bouts 2.6 - 15% greater with GPLC. Significant statistical interactions were detected between bout order and condition for both PP and MP (p < 0.05). There was a significant main effect of condition for LAC, LAC values 15.7% lower 4 min post-exercise with GPLC (p = 0.09) and with GPLC resulting in 16.2% less LAC at 14 min post-exercise (p < 0.05).

Conclusion: These findings indicate that short-term oral supplementation of GPLC can enhance peak power production in resistance trained males with significantly less LAC accumulation.

Figures

Figure 1
Figure 1
Peak power (PP) determined during repeated cycling sprints with Placebo (dotted columns) and with GPLC (darkened columns). Note: Significant condition main effect (p < 0.01) and interaction effect (p < 0.05). Significant paired time contrasts for sprints 3, 4, and 5 (p < 0.05). Values are mean ± SD. * denotes statistically significant difference between conditions (p < 0.05)
Figure 2
Figure 2
Mean power (MP) determined during repeated cycling sprints with Placebo (dotted columns) and with GPLC (darkened columns). Note: Significant interaction effect (p < 0.05). Significant paired time contrasts for sprints 4 and 5 (p < 0.05). Values are mean ± SD. * denotes statistically significant difference between conditions (p < 0.05)
Figure 3
Figure 3
Decrement in power output (DEC) determined during repeated cycling sprints with Placebo (dotted columns) and with GPLC (darkened columns). Note: No significant main condition or interaction effects (p > 0.05). Significant paired time contrast for sprint 5 (p < 0.05). Values are mean ± SD
Figure 4
Figure 4
Lactate (PP) assessed during at rest and 4 min and 14 min following repeated cycling sprints with Placebo (dotted columns) and with GPLC (darkened columns). Note: Significant condition main effect (p < 0.05). Significant paired time contrast for 14 min post sprints (p < 0.05) but not 4 min post sprint (p = 0.09). * denotes statistically significant difference between conditions (p < 0.05)
Figure 5
Figure 5
Heart rate (HR) assessed at rest, during and following repeated cycling sprints with Placebo (dotted columns) and with GPLC (darkened columns). Values are mean ± SD.

References

    1. Hamman JJ, Kluess HA, Buckwalter JB, Clifford PS. Blood flow response to muscle contractions is more closely related to metabolic rate than contractile work. J Appl Physiol. 2005;98:2096–2100. doi: 10.1152/japplphysiol.00400.2004.
    1. Naik JS, Valic Z, Buckwalter JB, Clifford PS. Rapid vasodilation in response to a brief titanic muscle contraction. J Appl Physiol. 1999;87:1741–1746.
    1. Anderson P, Saltin B. Maximal perfusion of skeletal muscle in man. J Physiol-London. 1985;366:233–249.
    1. Haddy FJ, Scott JB. Metabolic factors in peripheral circulatory regulation. Fed Proc. 1975;34:2006–2011.
    1. Kurjiaka DT, Segal SS. Conducted vasodilation elevates flow in arteriole networks of hamster striated muscle. Am J Physiol. 1995;269:H1723–H1728.
    1. Tschakovsky ME, Joyner MJ. Nitric oxide and muscle blood flow in exercise. Appl Physiol Nutr Metab. 2007;33:151–161. doi: 10.1139/H07-148.
    1. Hishikawa K, Nakaki T, Tsuda M, Esumi H, Oshima H, et al. Effects of systemic L-arginine administration on hemodynamics and nitric oxide release in man. Jpn Heart J. 1992;33:41–48.
    1. Bode-Boger SM, Boger RH, Galland A, Tsikas D, Frolich J. L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodymanic relationship. Br J Clin Pharmacol. 1998;46:489–497. doi: 10.1046/j.1365-2125.1998.00803.x.
    1. Brass EP. Supplemental carnitine and exercise. Am J Clin Nutr. 2000;72:618S–623S.
    1. Adams MR, Forsyth CJ, Jessup W, Robinson J, Celermajer DS. Oral arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. J Amer Col Cardiology. 1995;26:1054–1061. doi: 10.1016/0735-1097(95)00257-9.
    1. Chin-Dusting JP, Alexander CT, Arnold PJ, Hodgson WC, Lux AS, Jennings GL. Effects of in vivo and in vitro L-arginine supplementation on healthy human vessels. J Cardiovasc Pharmacol. 1996;28:158–166. doi: 10.1097/00005344-199607000-00023.
    1. Marconi C, Sessi G, Carpinelli A, Cerretelli P. Effects of L-carnitine loading on the aerobic and anaerobic performance of endurance athletes. Eur J Appl Physiol. 1985;54:131–135. doi: 10.1007/BF02335919.
    1. Bloomer RJ, Smith WA, Fisher-Wellman KH. Glycine propionyl-L-carnitine increases plasma nitrate/nitrite in resistance trained men. J Int Soc Sports Nutr. 2007;4:22. doi: 10.1186/1550-2783-4-22.
    1. Brass EP, Hiatt WR. The role of carnitine and carnitine supplementation during exercise in man and in individuals with special needs. J Am Coll Nutr. 1998;17:207–215.
    1. Heinonen OJ. Carnitine and physical exercise. Sports Med. 1996;22:109–132. doi: 10.2165/00007256-199622020-00005.
    1. Dragan GI, Vasiliu A, Georgescu E, Dumas I. Studies concerning chronic and acute effects of L-carnitine on some biological parameters in elite athletes. Physiologie. 1987;24:23–28.
    1. Vecchiet L, Di Lisa F, Pieralisi G, et al. Influence of L-carnitine supplementation on maximal exercise. Eur J Appl Physiol. 1990;61:486–490. doi: 10.1007/BF00236072.
    1. Siliprandi N, Di Lisa F, Pieralisi G, et al. Metabolic changes induced by maximal exercise in human subjects following L-carnitine administration. Biochim Biophys Acta. 1990;1034:17–21.
    1. Bloomer RJ. The role of nutritional supplements in the prevention and treatment of resistance exercise-induced skeletal muscle injury. Sports Med. 2007;37:519–532. doi: 10.2165/00007256-200737060-00005.
    1. Kraemer WJ, Volek JS, Dunn-Lewis C. L-carnitine supplementation: Influence upon physiological function. Curr Sports Med Rep. 2008;7:218–223.
    1. Stephens FB, Constantin-Teodosiu D, Laithwaite D, Simpson EJ, Greenhaff PL. Insulin stimulates L-carnitine accumulation in human skeletal muscle. FASEB J. 2005;20:377–379.
    1. Stephens FB, Constantin-Teodosiu D, Laithwaite D, Simpson EJ, Greenhaff PL. An acute increase in skeletal muscle carnitine content alters fuel metabolism in resting human skeletal muscle. J Clin EndoMetab. 2006;91:5013–5018. doi: 10.1210/jc.2006-1584.
    1. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. Clin Invest. 1994;94:1172–1179. doi: 10.1172/JCI117433.
    1. Arenas J, Huertas R, Campos Y, Diaz E, et al. Respiratory chain enzymes in muscle of endurance athletes: effect of L-carnitine. Biochem Biophys Res Commun. 1992;188:102–107. doi: 10.1016/0006-291X(92)92355-2.
    1. Arenas J, Ricox JR, Encinas AR, Pola P, et al. Effects of L-carnitine on the pyruvate dehydrogenase complex and carnitine palmitoyl transferase activities in muscle of endurance athletes. FEBS Lett. 1994;341:91–93. doi: 10.1016/0014-5793(94)80246-7.
    1. Huertas R, Campos Y, Diaz E, et al. Respiratory chain enzymes in muscle of endurance athletes: effect of L-carnitine. Biochem Biophys Res Commun. 1992;188:102–107. doi: 10.1016/0006-291X(92)92355-2.
    1. Anand I, Chandrashekhan Y, De Guili F, Pasini E, et al. Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther. 1998;12:291–299. doi: 10.1023/A:1007721917561.
    1. Dal Lago A, De Martini D, Flore R, et al. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. Drugs Exp Clin Res. 1999;25:29–36.
    1. Podoprigora GI, Nartsissov YR, Aleksandrov PN. Effect of glycine on microcirculation in pial vessels of rat brain. Bull Exp Biol Med. 2005;139:675–677. doi: 10.1007/s10517-005-0375-2.
    1. Smith WA, Fry AC, Tschume LC, Bloomer RJ. Effect of glycine propionyl-L-carnitine on aerobic and anaerobic performance. Int J Sport Nutr Exerc Metab. 2008;18:19–36.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren